Ashok K. Malani, MD; Hussam Ammar, MD
Potential Financial Conflicts of Interest: None disclosed.
Malani AK, Ammar H. Cryptogenic Stroke and Patent Foramen Ovale. Ann Intern Med. 2006;145:393-394. doi: 10.7326/0003-4819-145-5-200609050-00017
Download citation file:
Published: Ann Intern Med. 2006;145(5):393-394.
TO THE EDITOR:
In their comprehensive and informative Update (1), Drs. Holloway and Józefowicz suggest using warfarin for secondary prevention of stroke in patients with atrial septal defect. The current literature has no strong evidence to support this view, and therefore the current guidelines from the American Academy of Neurology state that “the evidence is insufficient to determine whether aspirin or warfarin is superior in preventing recurrent stroke or death in patients with patent foramen ovale (PFO) alone” (2). However, the American Academy of Neurology does recommend warfarin therapy in patients with patent foramen ovale and evidence of deep venous thrombosis (2).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only